Detection of novel diagnostic antibodies in ankylosing spondylitis: An overview

Quaden, Dana H.F.; Winter, L. De; Somers, Veerle

doi:10.1016/j.autrev.2016.06.001

Cited by 44 publications

(41 citation statements)

References 142 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Earlier diagnosis and treatment are urgently required and effective in reducing disease burden of AS patients while both of them are usually impeded due to the seronegative character and the absence of hallmark. Thus a number of emerging researches are focusing on the new biomarkers and antibodies, which can not only contribute to the diagnosis, but also reflect disease activity and curative effect [ 5 , 23 ], while the currently new biomarkers are still elusive due to the inconsistent results of different researches as well as lacking of multicenter studies. Therefore, only HLA-B27 and inflammatory marker CRP are widely accepted as routinely clinical biomarkers of AS.…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, only HLA-B27 and inflammatory marker CRP are widely accepted as routinely clinical biomarkers of AS. Detecting HLA-B27 is useful only if AS is strongly suspected due to lack of specificity [ 5 , 24 ]. Moreover, only half of the AS patients with the evaluated CRP and earlier studies indicated the poor predictive value of CRP and the poor correlation with BASDAI [ 25 , 26 ]; however, a study in 2010 showed a significant correlation between CRP and disease activity [ 27 ].…”

Section: Discussionmentioning

confidence: 99%

“…However, recent genome-wide association studies (GWASs) have identified that some single nucleotide polymorphisms (SNPs) were associated with AS. Many of these gene loci assemble in dissimilar immunoregulatory pathways [ 4 ], which are related to NF- κ B signaling, IL-23 pathway, and T cell phenotype as well as antigen presentation [ 5 , 6 ]. Inflammation and new bone formation are considered as the critical factors of AS, within the genetically susceptible individuals.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Serum HMGB1 Serves as a Novel Laboratory Indicator Reflecting Disease Activity and Treatment Response in Ankylosing Spondylitis Patients

Wang

Miao

et al. 2016

Journal of Immunology Research

View full text Add to dashboard Cite

Objective. High mobility group box 1 (HMGB1) is a late inflammatory factor participating in the pathogenesis of various autoimmune and inflammatory diseases. In the current study, we analyzed the association between serum levels of HMGB1 and clinical features of AS patients before and during treatment. Methods. Serum HMGB1 was detected in 147 AS patients and 61 healthy controls using ELISA. We evaluated the association between HMGB1 and extra-articular manifestations as well as disease severity indices. Among these AS patients, 41 patients received close follow-up at 1, 3, and 6 months after treatment. This group comprised 25 patients treated with anti-TNF-α biologics and 16 patients receiving oral NSAIDs plus sulfasalazine. Results. The serum HMGB1 of AS patients was significantly higher than in healthy controls and positively correlated with BASDAI, BASFI, ASDAS-ESR, ASDAS-CRP, ESR, and CRP, but not with HLA-B27, anterior uveitis, and recurrent diarrhea. There was no significant difference between patients with radiographic damage of hip joints and those without. We observed that serum HMGB1 paralleled disease activity after treatment. Conclusion. Serum level of HMGB1 is higher in AS patients, and to some extent, HMGB1 can reflect the activity of AS and be used as a laboratory indicator to reflect the therapeutic response.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Serum HMGB1 Serves as a Novel Laboratory Indicator Reflecting Disease Activity and Treatment Response in Ankylosing Spondylitis Patients

Wang

Miao

et al. 2016

Journal of Immunology Research

View full text Add to dashboard Cite

show abstract

“…Currently, interests have been drawn toward the collaboration and interaction between genetic and environmental factors that finally impress the epigenome (Mahmoudi, Aslani, Nicknam, Karami, & Jamshidi, ; Quaden, De Winter, & Somers, ). Considering these facts, to explain the etiology of DDH, epigenetics has a unique importance.…”

Section: Discussionmentioning

confidence: 99%

DNA hypermethylation of GDF5 in developmental dysplasia of the hip (DDH)

Baghdadi

Nejadhosseinian

Shirkoohi

et al. 2019

Molec Gen & Gen Med

View full text Add to dashboard Cite

Introduction & Objective Developmental Dysplasia of the Hip (DDH) is one of the most common congenital skeletal anomalies. Body of evidence suggests that genetic variations in GDF5 are associated with susceptibility to DDH. DDH is a multifactorial disease and its etiology has not been entirely determined. Epigenetic changes such as DNA methylation could be linked to DDH. In this scheme, we hypothesized that changes in GDF5 DNA methylation could predispose a susceptible individual to DDH. Methods This study consisted of 45 DDH patients and 45 controls with healthy femoral neck cartilage, who underwent hemi‐, or total arthroplasty for the femoral neck fracture. A cartilage sample of 1 cm in diameter and 1 mm in the thickness was obtained for DNA extraction. DNA was extracted and DNA methylation of GDF5 was evaluated by metabisulfite method. Results Methylation analysis showed that the promoter of GDF5 in cartilage samples from DDH patients was hypermethylated in comparison to healthy controls (p = .001). Conclusion Our study showed that the methylation status of the GDF5 in patients with DDH is dysregulated. This dysregulation indicates that adjustment in the methylation might modify the expression of this gene. Since this gene plays an essential role in cartilage and bone development, thus reducing its expression can contribute to the pathogenesis of DDH. Further studies are needed to elucidate the role of GDF5 in this disease.

show abstract

“…Autoantibodies in seronegative diseases have been reported before . Wright and colleagues used a nucleic acid programmable protein array to test the reactivity of AS serum against 3,498 human proteins plated in 2 arrays .…”

mentioning

confidence: 99%

Thinking Positive in Spondyloarthritis

Haroon

2019

Arthritis & Rheumatology

View full text Add to dashboard Cite

Detection of novel diagnostic antibodies in ankylosing spondylitis: An overview

Cited by 44 publications

References 142 publications

Serum HMGB1 Serves as a Novel Laboratory Indicator Reflecting Disease Activity and Treatment Response in Ankylosing Spondylitis Patients

Serum HMGB1 Serves as a Novel Laboratory Indicator Reflecting Disease Activity and Treatment Response in Ankylosing Spondylitis Patients

DNA hypermethylation of GDF5 in developmental dysplasia of the hip (DDH)

Thinking Positive in Spondyloarthritis

Contact Info

Product

Resources

About